Related Experiment Video
Updated: Aug 15, 2026
Intravenous Injections in Neonatal Mice
Published on: November 11, 2014
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS
W A Sheremata1, T L Vollmer, L A Stone
1University of Miami, Department of Neurology, School of Medicine, FL 33136, USA. wsherema@mednet.med.miami.edu
Abstract:
A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.
More Related Videos
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019